ChemoCentryx Inc (NASDAQ:CCXI) insider Pui San Kwan sold 1,000 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $39.02, for a total transaction of $39,020.00. Following the sale, the insider now owns 20,434 shares of the company’s stock, valued at approximately $797,334.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Pui San Kwan also recently made the following trade(s):

  • On Monday, January 6th, Pui San Kwan sold 122,912 shares of ChemoCentryx stock. The stock was sold at an average price of $34.57, for a total transaction of $4,249,067.84.

Shares of CCXI traded up $1.22 during trading hours on Tuesday, hitting $37.91. The company’s stock had a trading volume of 468,432 shares, compared to its average volume of 700,767. The company has a market cap of $2.20 billion, a price-to-earnings ratio of -49.88 and a beta of 2.28. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.12 and a quick ratio of 3.12. The business has a 50 day simple moving average of $33.58 and a two-hundred day simple moving average of $14.25. ChemoCentryx Inc has a 52-week low of $6.16 and a 52-week high of $39.80.

ChemoCentryx (NASDAQ:CCXI) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.06. The firm had revenue of $10.58 million during the quarter, compared to the consensus estimate of $7.83 million. ChemoCentryx had a negative net margin of 143.30% and a negative return on equity of 88.76%. Research analysts predict that ChemoCentryx Inc will post -0.98 earnings per share for the current year.

A number of analysts recently issued reports on the stock. ValuEngine downgraded shares of ChemoCentryx from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. Piper Jaffray Companies raised their price objective on shares of ChemoCentryx from $17.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, November 26th. JPMorgan Chase & Co. raised their price objective on shares of ChemoCentryx from $14.00 to $28.00 and gave the stock a “positive” rating in a report on Tuesday, November 26th. BidaskClub downgraded shares of ChemoCentryx from a “buy” rating to a “hold” rating in a report on Tuesday, January 7th. Finally, Canaccord Genuity raised their price objective on shares of ChemoCentryx from $16.00 to $48.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. ChemoCentryx has a consensus rating of “Buy” and a consensus price target of $40.29.

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. increased its stake in shares of ChemoCentryx by 45.4% in the second quarter. BlackRock Inc. now owns 3,852,875 shares of the biopharmaceutical company’s stock worth $35,832,000 after purchasing an additional 1,202,155 shares in the last quarter. Farallon Capital Management LLC increased its stake in shares of ChemoCentryx by 33.3% in the second quarter. Farallon Capital Management LLC now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $18,600,000 after purchasing an additional 500,000 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of ChemoCentryx by 37.9% in the second quarter. Vanguard Group Inc. now owns 1,774,489 shares of the biopharmaceutical company’s stock worth $16,502,000 after purchasing an additional 488,063 shares in the last quarter. Renaissance Technologies LLC grew its stake in ChemoCentryx by 29.3% during the second quarter. Renaissance Technologies LLC now owns 1,465,381 shares of the biopharmaceutical company’s stock valued at $13,628,000 after acquiring an additional 332,127 shares in the last quarter. Finally, Nuveen Asset Management LLC purchased a new position in ChemoCentryx during the second quarter valued at approximately $3,750,000. Hedge funds and other institutional investors own 60.72% of the company’s stock.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.

See Also: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Insider Buying and Selling by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.